Janus Henderson Group PLC trimmed its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 1.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,158,205 shares of the medical research company’s stock after selling 67,909 shares during the period. Janus Henderson Group PLC owned 7.54% of NeoGenomics worth $80,734,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of the stock. Quantitative Systematic Strategies LLC acquired a new stake in NeoGenomics in the 1st quarter valued at approximately $100,000. Campbell & CO Investment Adviser LLC grew its holdings in NeoGenomics by 64.3% in the 1st quarter. Campbell & CO Investment Adviser LLC now owns 17,127 shares of the medical research company’s stock valued at $140,000 after buying an additional 6,700 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in NeoGenomics in the 1st quarter valued at approximately $152,000. Wrapmanager Inc. grew its holdings in NeoGenomics by 36.6% in the 1st quarter. Wrapmanager Inc. now owns 26,857 shares of the medical research company’s stock valued at $219,000 after buying an additional 7,192 shares during the last quarter. Finally, FDx Advisors Inc. grew its holdings in NeoGenomics by 19.9% in the 1st quarter. FDx Advisors Inc. now owns 30,644 shares of the medical research company’s stock valued at $250,000 after buying an additional 5,091 shares during the last quarter. 81.07% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:NEO opened at $13.79 on Wednesday. NeoGenomics, Inc. has a 1-year low of $7.08 and a 1-year high of $15.00. The company has a market cap of $1.13 billion, a PE ratio of 229.83 and a beta of 0.59. The company has a current ratio of 1.74, a quick ratio of 1.59 and a debt-to-equity ratio of 0.77.
NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, July 24th. The medical research company reported $0.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.01. NeoGenomics had a negative return on equity of 0.36% and a negative net margin of 0.98%. The company had revenue of $67.70 million for the quarter, compared to analyst estimates of $66.40 million. During the same quarter last year, the firm earned $0.04 EPS. NeoGenomics’s revenue for the quarter was up 8.7% compared to the same quarter last year. research analysts expect that NeoGenomics, Inc. will post 0.08 EPS for the current year.
A number of analysts have issued reports on the company. Leerink Swann assumed coverage on NeoGenomics in a report on Tuesday, August 21st. They issued an “outperform” rating and a $18.00 target price on the stock. BidaskClub lowered NeoGenomics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 10th. Zacks Investment Research lowered NeoGenomics from a “hold” rating to a “sell” rating in a report on Thursday, July 19th. Stephens reaffirmed a “buy” rating and issued a $15.00 target price on shares of NeoGenomics in a report on Tuesday, June 26th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $15.00 target price on shares of NeoGenomics in a report on Thursday, June 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $18.63.
In related news, insider Robert J. Shovlin sold 12,941 shares of the business’s stock in a transaction on Friday, June 29th. The stock was sold at an average price of $13.12, for a total value of $169,785.92. Following the sale, the insider now owns 39,884 shares of the company’s stock, valued at approximately $523,278.08. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Steven C. Jones sold 2,000 shares of the business’s stock in a transaction on Friday, June 15th. The shares were sold at an average price of $13.25, for a total value of $26,500.00. Following the completion of the sale, the executive vice president now directly owns 241,815 shares in the company, valued at approximately $3,204,048.75. The disclosure for this sale can be found here. Insiders have sold a total of 513,041 shares of company stock worth $7,064,707 in the last three months. 12.20% of the stock is owned by insiders.
NeoGenomics Company Profile
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.
See Also: How to Use the New Google Finance Tool
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.